Skip to content

Phase II study of stereotactic MR-guided online adaptive radiosurgery for small lung cancer

Phase II study of stereotactic MR-guided online adaptive radiosurgery for small lung cancer - Stereotactic adaptive radiosurgery for small lung cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000054375
Enrollment
25
Registered
2024-06-01
Start date
2024-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary lung cancer, metastatic lung cancer

Interventions

To perform stereotactic MR-guided online adaptive radiosurgery for small lung cancer

Sponsors

Tohoku University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Pathologically or clinically diagnosed primary lung cancer or solitary metastatic lung cancer: lack of or controlled lymph node metastasis, pulmonary metastasis, and other distant metastases 2.Lung tumor was 5 cm or less in diameter and was not attached to chest wall 3.Tumor was not adjacent organ at risk: trachea, main~lobar bronchus, heart, spinal cord, brachial plexus, esophagus, stomach 4.Forced expiratory volume 1.0:700 mL <= 5.Performance status(ECOG):0-2 6.Medically inoperable or patient who refused surgery 7.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Patients with severe complications such as uncontrolled diabetes, collagen disease, heart disease, lung disease, kidney disease, and mental illness 2.Receiving home oxygen therapy 3.Pregnant, lactating, or likelihood of pregnancy 4.Active infectious disease 5.History of radiation therapy that may overlap with the current treatment 6.Presence of obvious interstitial shadows on CT images 7.Cases with pacemakers, implanted defibrillators, or other internal metals incompatible with MRI 8.Claustrophobia preventing MRI examination 9.Patients with psychiatric illness or symptoms making participation in the study difficult to assess

Design outcomes

Primary

MeasureTime frame
One-year local control and incidences of rib fracture

Secondary

MeasureTime frame
One-year overall survival time One-year progression free survival Incidences of serious adverse events

Countries

Japan

Contacts

Public ContactTakaya Yamamoto

Tohoku University Hospital Department of Radiation Oncology

takaya.yamamoto.c3@tohoku.ac.jp+81-22-717-7312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026